利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.021 秒)

    METHODS OF IDENTIFYING AND ISOLATING STEM CELLS AND CANCER STEM CELLS
    12.
    发明公开
    METHODS OF IDENTIFYING AND ISOLATING STEM CELLS AND CANCER STEM CELLS 审中-公开
    鉴定和分离干细胞和癌症干细胞的方法

    公开(公告)号：EP1530418A2

    公开(公告)日：2005-05-18

    申请号：EP03741851.4

    申请日：2003-05-30

    申请人： The Board of Trustees of the Leland Stanford Junior University

    发明人： JAMIESON, Catriona Helen M. ,  AILLES, Laurie ElizabethStanford University ,  REYA, Tannishtha ,  WEISSMAN, Irving, L.

    IPC分类号： A01N1/00 ,  A01N1/02 ,  C12N5/00

    CPC分类号： C12Q1/6897 ,  C12N5/0647 ,  C12Q1/6881 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156

    摘要： Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

    摘要翻译： 提供了用于鉴定干细胞和癌症干细胞的方法和组合物。 β-连环蛋白也被确定为开发针对造血肿瘤（即白血病和淋巴瘤细胞）的治疗部分的靶标，其可以包括针对β-连环蛋白的筛选测定或β-连环蛋白信号传导途径的成员。 造血细胞中的细胞增殖可通过将稳定的β-连环蛋白引入造血细胞而改变，造血细胞的凋亡能力发生改变但未完全转化。 永生化细胞可用于筛选试验以及分析造血细胞经历转化的途径。

    MAMMALIAN MYELOID PROGENITOR CELL SUBSETS
    16.
    发明公开
    MAMMALIAN MYELOID PROGENITOR CELL SUBSETS 有权
    在骨髓祖细胞哺乳动物为单位

    公开(公告)号：EP1194035A1

    公开(公告)日：2002-04-10

    申请号：EP00946928.9

    申请日：2000-06-29

    申请人： The Board of Trustees of The Leland Stanford Junior University

    发明人： WEISSMAN, Irving, L. ,  TRAVER, David, Jeffrey ,  AKASHI, Koichi

    IPC分类号： A01N1/02 ,  C12N5/06 ,  C12Q1/68

    CPC分类号： C12Q1/6881 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/26 ,  C12N2503/00 ,  C12Q2600/158

    摘要： A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

    COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCE
    19.
    发明公开
    COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCE 审中-公开
    诱导MHC I类阳性细胞的细胞吞噬作用和对抗CD47 / SIRPA抗性的组合物和方法

    公开(公告)号：EP3209769A1

    公开(公告)日：2017-08-30

    申请号：EP15853503.9

    申请日：2015-10-23

    申请人： The Board of Trustees of the Leland Stanford Junior University

    发明人： MAUTE, Roy, Louis ,  WEISKOPF, Kipp, Andrew ,  RING, Aaron, Michael ,  WEISSMAN, Irving, L.

    IPC分类号： C12N5/078 ,  C12N5/0786

    CPC分类号： C07K16/2833 ,  A61K38/1774 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

    摘要： Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

    摘要翻译： 提供了用于诱导靶细胞的吞噬作用，治疗患有癌症的个体，治疗患有细胞内病原体感染（例如慢性感染）的个体，和/或减少受体细胞（例如癌细胞， 感染细胞内病原体的细胞等）。 还提供了方法和组合物用于预测个体是否对用抗-CD47 / SIRPA剂治疗具有抗性（或易感）。 在一些情况下，本发明的方法和组合物包括抗MHC I类/ LILRB1剂。 在一些情况下，本发明的方法和组合物包括抗MHC I类/ LILRB1试剂和抗CD47 / SIRPA试剂（例如，共同施用抗MHC I类/ LILRB1试剂和抗CD47 / SIRPA 剂）。 还提供了用于实施本公开的方法的试剂盒。